Eczema Agents Systemic Interleukin-13 (IL-13)Antag.mAb

The phrase "Eczema Agents Systemic Interleukin-13 (IL-13)Antag.mAb" is a formulary and compendial drug classification rather than a formal FDA established pharmacologic class, though it corresponds to systemic interleukin-13 antagonist monoclonal antibodies

The phrase "Eczema Agents Systemic Interleukin-13 (IL-13)Antag.mAb" is a formulary and compendial drug classification rather than a formal FDA established pharmacologic class, though it corresponds to systemic interleukin-13 antagonist monoclonal antibodies

Biologic therapies within this group, such as lebrikizumab and tralokinumab, selectively bind to the circulating cytokine interleukin-13 to prevent its interaction with receptor complexes, thereby disrupting the downstream type-2 inflammatory signaling cascade These systemic subcutaneous agents are primarily indicated for the treatment of moderate-to-severe atopic dermatitis in patients whose disease is insufficiently controlled with topical prescription therapies or when those treatments are cl...

Biologic therapies within this group, such as lebrikizumab and tralokinumab, selectively bind to the circulating cytokine interleukin-13 to prevent its interaction with receptor complexes, thereby disrupting the downstream type-2 inflammatory signaling cascade

These systemic subcutaneous agents are primarily indicated for the treatment of moderate-to-severe atopic dermatitis in patients whose disease is insufficiently controlled with topical prescription therapies or when those treatments are clinically inadvisable